Chemistry:AB-MDMSBA
From HandWiki
AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.[1][2]
It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB.[3] This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB2 over CB1.[4] The activity of AB-MDMSBA against either cannabinoid receptor is unknown.
See also
References
- ↑ "Synthetic cannabinoid AB-MDMSBA found in 'benzodiazepine' samples - The Know" (in en). 2024-12-10. https://theknow.org.au/alerts_warnings/synthetic-cannabinoid-ab-mdmsba-found-in-benzodiazepine-samples/.
- ↑ "New synthetic cannabinoid misrepresented as a benzodiazepine" (in en). https://www.highalert.nz/alerts-and-notifications/new-synthetic-cannabinoid-misrepresented-as-a-benzodiazepine/.
- ↑ "Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies" (in en). Bioorganic & Medicinal Chemistry Letters 17 (1): 272–277. January 2007. doi:10.1016/j.bmcl.2006.09.049. PMID 17027269. https://linkinghub.elsevier.com/retrieve/pii/S0960894X06011061.
- ↑ "CB2 selective sulfamoyl benzamides: Optimization of the amide functionality" (in en). Bioorganic & Medicinal Chemistry Letters 19 (2): 309–313. January 2009. doi:10.1016/j.bmcl.2008.11.091. PMID 19091565. https://linkinghub.elsevier.com/retrieve/pii/S0960894X08014765.
 |  |
